MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Prematu... ( Prospective Study Seeks to Assess RSV...)

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants

Date:6/29/2009

Prospective Study Seeks to Assess RSV Burden in Outpatient Setting During First Year of Life; Reinforcing Commitment to Pediatric Research

GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune continues to advance its commitment to pediatric research with today's announcement of the first observational prospective study designed to assess the burden of respiratory syncytial virus (RSV) among preterm infants 32-to-35 weeks gestational age (GA) in outpatient settings during their first year of life.

The study also seeks to gather virology data regarding the national onset of the RSV season across the four geographic regions established by the U.S. Centers for Disease Control & Prevention. Additionally, this two-year observational study will look to identify the preterm infants that may be most susceptible to serious RSV infection and the factors that may elevate that risk.

"More than 98 percent of all children contract RSV before their second birthday. Some of these children will be hospitalized and for many more, the severity of the infection forces them to visit a healthcare provider or hospital clinic on an outpatient basis," said Jessie Groothuis, M.D., MedImmune vice president, medical and scientific affairs, infectious disease. "The intent of this first-of-its-kind prospective study is to add to the body of evidence surrounding RSV burden of disease; gaining a snapshot of when the RSV season starts and stops; as well as gathering insight into what risk factors may make preterm infants most susceptible to RSV infection and to serious RSV-related illness."

She went on to say that this information may help pediatricians, payers and health policy makers make better decisions regarding the use of finite healthcare resources on behalf of under-represented and under-served 32-to-35 weeks (GA) preterm infants.

This observational, prospective study will cover two consec
'/>"/>

SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
4. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
5. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
11. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

Post Your Comments:

(Date:12/15/2009)... Conn., Dec. 15 Rib-X Pharmaceuticals, Inc., ... commercialization of novel drugs for the treatment of ... into a collaborative research agreement with Massachusetts General ... plan for the collaboration, Dr. David Hooper of ... an established animal model to determine resistance development ...

(Date:12/15/2009)... 15 Arlington Medical Resources (AMR) and ... (MRSA) is the most concerning pathogen to ... their treatment of skin and skin structure infections. ... top factors that influences European physician drug selection ... key factors that drive prescribing include an agent,s ...

(Date:12/15/2009)... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a ... announced today,that Weidong Yin, Chairman, President & ... to be one of 18 nominees for ... CCTV,s Economic Man-of-the-Year is the country,s ... to as the "Oscar Award of the,Chinese ...

Breaking Medicine Technology:Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2 Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3 Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 2 Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 3 Healthcare Staffing Company Medical Solutions Named Among 26quot 3B2009 Best Places to Work in Omaha 26quot 3B 50145 1 Healthcare Staffing Company Medical Solutions Named Among 26quot 3B2009 Best Places to Work in Omaha 26quot 3B 50145 2 Healthcare Staffing Company Medical Solutions Named Among 26quot 3B2009 Best Places to Work in Omaha 26quot 3B 50145 3 Healthcare Staffing Company Medical Solutions Named Among 26quot 3B2009 Best Places to Work in Omaha 26quot 3B 50145 4 Sudden Cardiac Arrest Foundation Mourns the Loss of Michael Jackson 50143 1 Sudden Cardiac Arrest Foundation Mourns the Loss of Michael Jackson 50143 2 Latin America must cut blood pressure to thrive 50141 1 Latin America must cut blood pressure to thrive 50141 2 Latin America must cut blood pressure to thrive 50141 3

[0] Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital [0] A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections [0] Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award

... Oct. 18 Posit Science Corporation,announced today that ... an,innovative computerized training program designed to enhance memory. ... study has now enrolled more than five hundred ... and contribute to scientific,research. Principal Investigators for ...

... 18 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ... be,presenting clinical and preclinical data on its ... of the American Association for,Cancer Research (AACR), ... Research and Treatment of Cancer (EORTC) entitled,"International ...

Other Medicine Technology:Study Demonstrates Mindful Approach to Aging 2 Study Demonstrates Mindful Approach to Aging 3 Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2

Study Demonstrates Mindful Approach to Aging Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

(Date:12/15/2009)... Study examines potential for injury when doctors decide benefits ... (HealthDay News) -- MRI scans can pose a serious ... U.S. Food and Drug Administration researchers exposed pacemakers to ... electrical voltage produced at the tip of the pacemaker ... patient,s heart. , The exposure to MRI magnetic pulses ...

(Date:12/15/2009)... ANGELES, Dec. 15 Accelify is proud to ... Board of Advisors. David will serve as Director of ... join Accelify,s National Board of Advisors. ,, ... School District,s Board of Education in June 1995. As ... population of over 600,000 stretching from Northeast Los Angeles ...

(Date:12/15/2009)... -- Mergers and acquisitions are commonplace today. As ... or complete a product portfolio they also must ... programs. ,, A new free, white paper from ... Hearing Conservation Program: US Airways ," details how ... led the newly formed company to enhance its ...

(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... of Autoimmune Diseases Therapeutics - Market ... Pipeline and Deals Analysis ... Summary ,, The author has ...

(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...

[0] Patients With Pacemakers Should Avoid MRI Scans [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs

... hay fever might enjoy a surprise benefit, according to research ... In a paper presented at an international symposium in Sydney, ... diseases are up to 25 percent less likely to get ... InterLymph Symposium is co-hosted by the Leukaemia Foundation, the Cancer ...

... quits , , TUESDAY, July 29 (HealthDay News) -- Nonsmokers who ... experiencing a stroke, a new study suggests. , Researchers also ... smoke carry an even greater risk for stroke. However, nonsmoking ... higher risk for stroke than those married to someone who ...

... new method to close wounds, of practically ... and scarring, ALMONTE, Ontario, July 29 Canica ... awarded its first,U.S. patent in a series of comprehensive ... closure of wounds of all,kinds., The extensive multi-national ...

... 29 DoctorDirectory.com, Inc.,announced that it ... to,co-market VoSpire ER(R) (Albuterol Sulfate) Extended-Release ... IncreaseRx utilizes,web-based educational and promotional tactics ... prescribers with targeted sales and marketing ...

... Quarter Results to be Reported Wednesday, August 6th After Market ... ... The Providence Service,Corporation (Nasdaq: PRSC ) today announced that primarily ... that,fund the services the Company provides, diluted earnings per share for the,second ...

... IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), a ... it will report,results for its second quarter 2008 ended ... market close., A conference call to review the ... on August 12, 2008 and will be hosted by ...

Other Medicine News:Health News:Hey fever! The surprise benefit of allergies 2 Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2 Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3 Health News:Canica Design Awarded Milestone U.S. Patent for Dynamic Wound Closure Systems 2 Health News:Canica Design Awarded Milestone U.S. Patent for Dynamic Wound Closure Systems 3 Health News:DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc. 2 Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 2 Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 3 Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 4 Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 5 Health News:IPC The Hospitalist Company, Inc. to Report Second Quarter 2008 Financial Results 2

Hey fever! The surprise benefit of allergies Secondhand Smoke Raises Stroke Risk for Spouses Canica Design Awarded Milestone U.S. Patent for Dynamic Wound Closure Systems DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 IPC The Hospitalist Company, Inc. to Report Second Quarter 2008 Financial Results

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

Medicine Products:

Complement Component 3 Complement Component 1Q Level Complement CH100, Total Complement Activity Enzyme Immunoassay, Total

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Prematu...( Prospective Study Seeks to Assess RSV...),Health